Publications by authors named "Gloria D Berges"
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Front Immunol
November 2023
Article Synopsis
- BK-SE36/CpG is a malaria vaccine candidate that was tested for safety and immune response in healthy, malaria-exposed participants in Burkina Faso.
- In a clinical trial involving 135 participants across different age groups, the vaccine was well tolerated with no severe adverse events linked to it, although mild to moderate side effects like pain and fever were noted.
- The vaccine elicited stronger immune responses in younger age groups, with participants showing higher antibody levels after the final dose compared to earlier doses.
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines.
Methods: We conducted a randomized, double-blind, and controlled, phase 2 trial in Ouagadougou, Burkina Faso.
Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
Int J Infect Dis
January 2021
Objectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. The co-administration of Typbar TCV (Bharat Biotech International) with routine group A meningococcal conjugate vaccine (MCV-A) and measles-rubella (MR) vaccine was tested.
Methods: This was a double-blind, randomized controlled trial performed in Ouagadougou, Burkina Faso.